The use of mycophenolate mofetil in liver transplant recipients

Bibliography

• HELDERMAN JH, BENNETT WM,CIBRIK DM, KAUFMAN DB, KLEIN A, TAKEMOTO SK: Immunosuppression: practice and trends. Jim. .1 Transpl. (2003) 3:41–52.
   Google Scholar
• •A nice review of the modern practice of immunosuppression in solid organ transplant recipients.
   Google Scholar
• GOSIO B: Ricerche batteriologiche e chimiche sulle alterazion delmais; contributo alletiologica della pellagra. Ig. Sanita Pubblica Ann. (1896) 7:825.
   Google Scholar
• SUZUKI S, KIMURA T, ANKO K: Anitumoral activity of mycophenolic acid. Antibiot. (1969) 22:297–302.
   Google Scholar
• WILLIAMS RH, LIVELY DH, DELONG DC: Mycophenolic acid:antiviral and antitumor properties.Antibiot. (1968) 21:463–464.
   Google Scholar
• CARTER SB, FRANKLIN TJ, JONES DF, LEONARD BJ, MILLS SD,TURNER WB: Mycophenolic acid: ananti-cancer compound with unusualproperties. Nature (1969) 223:848.
   PubMed Web of Science ®Google Scholar
• BRE WIN TB, COLE MP, JONES CT: Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother. Rep. (1972) 56:83–87.
   PubMedGoogle Scholar
• FLOREY HW, GILLIVER K,JENNINGS MA: Mycophenolic acid: an antibiotic from Penicillium brevicopactum. Lancet (1946) 1:46–49.
   PubMed Web of Science ®Google Scholar
• MELE TS, HALLORAN PF: The use of mycophenolate mofetil in transplant recipients. Immunopharmacology (2000) 47:215–245.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the role of mycophenolate mofetil in transplant recipients.
   Google Scholar
• SWEENEY MJ, HOFFMAN DH,ESTERMAN MA: Metabolism and biochemistry of mycophenolic acid.Cancer Res. (1972) 32:1803–1809.
   Google Scholar
• LINTRUP J, HYLTOFT-PETERSEN P, KNUDTZON S: Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemothec Rep. (1972) 56:229–235.
   PubMedGoogle Scholar
• HALE MD, NICHOLLS AJ, BULLINGHAM RE et al.: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol Thec (1998) 64:672–683.
   PubMed Web of Science ®Google Scholar
• LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K, NELSON PH: Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharmacol Res. (1990) 7:161–166.
   Google Scholar
• PESCOVITZ MD, CONTI D, DUNN J et al.: Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin. Transplant. (2000) 14:179–188.
   PubMed Web of Science ®Google Scholar
• SHAW LM, KORECKA M, VENKATARAMANAN R, GOLDBERG L, BLOOM R, BRAYMAN KL: Mycophenolic acid pharmacodynamics and pharmocokinetics provide a basis for rational monitoring strategies. Am. J. Transpl (2003) 3:534–542.
   PubMed Web of Science ®Google Scholar
• OELLERICH M, SHIPKOVA M, SCHUTZ E et al.: Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther. Drug Monit. (2000) 22:20–26.
   Google Scholar
• WEBER LT, SHIPKOVA M, ARMSTRONG VW et al: The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. Am. Soc. Nephrol (2002) 13:759–768.
   PubMedGoogle Scholar
• JAIN A, VENKATARAMANAN R, HAMAD IS et al: Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. Clin. Pharmacol. (2001) 41:268–276.
   Google Scholar
• AW MM, BROWN NW, ITSUKA T et al: Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.Liver Transpl. (2003) 9:383–388.
   PubMed Web of Science ®Google Scholar
• GRASSER B, IBERER F,SCHAFFELLNER S et al: Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation.Transplant. Proc. (2001) 33:2154–2156.
   PubMedGoogle Scholar
• VAN GELDER T, KLUPP J,BARTEN MJ, CHRISTIANS U, MORRIS RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.Ther: Drug Monit. (2001) 23:119–228.
   PubMed Web of Science ®Google Scholar
• •A key evaluation on the effects of tacrolimus and cyclosporin A on mycophenolate acid pharmacokinetics.
   Google Scholar
• SMAK GREGOOR PJ, VAN GELDER T, HESSE CJ, VAN DER MAST BJ, VAN BESOUVV NM, WEIMAR W:Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.Nephrol. Dial. Transplant. (1999) 14:706–708.
   PubMed Web of Science ®Google Scholar
• NOWAK I, SHAW LM: Mycophenolateacid binding to human serum albumin: characterisation and relation to pharmacodynamics. Clin. Chem. (1995) 41:1011–1017.
   PubMed Web of Science ®Google Scholar
• KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G et al: The effect of renal insufficiency on mycophenolic acid protein binding. j. Clin. Pharmacol (1999) 39:715–720.
   PubMed Web of Science ®Google Scholar
• MEIER-KRIESCHE HU, SHAW LM, KORECKA M, KAPLAN B:Pharmacokinetics of mycophenolic acid inrenal insufficiency. Mei: Drug Monit. (2000) 22:27–30.
   PubMed Web of Science ®Google Scholar
• JAIN AB, HAMAD I, ZUCKERMAN S et al.: Effect oft-tube clamping on the pharmacolkinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Stow. (1999) 5:101–106.
   PubMedGoogle Scholar
• SCHMIDT LE, RASMUSSEN A, NORRELYKKE MR, POULSEN HE, HANSEN BA: The effect of selective bowel decontamination on the pharmacolkinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl (2001) 7:739–742.
   PubMedGoogle Scholar
• PLATZ KP, BECHSTEIN WO, ECKHOFF DE, SUZUKI Y, SOLLINGER HW: RS-61443 reverses acute allograft rejection in dogs. Surgery (1991) 110:736–740.
   PubMed Web of Science ®Google Scholar
• PLATZ KP, SOLLINGER HW, HULLETT DA, ECKHOFF DE, EUGUI EM, ALLISON AC: RS-61443-a new, potent immunosuppressive agent. Transplantation (1991) 51:27–31.
   PubMed Web of Science ®Google Scholar
• EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet (1995) 345:1321–1325.
   PubMed Web of Science ®Google Scholar
• THE TRICONTINENTALMYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP: A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1996) 61:1029–1037.
   PubMedGoogle Scholar
• SOLLINGER HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 60:225–232.
   PubMed Web of Science ®Google Scholar
• JAIN A, KASHYAP R, DODSON F et al.: A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation (2001) 72:1091–1097.
   PubMedGoogle Scholar
• STERNECK M, FISCHER L, GAHLEMANN C, GUNDLACH M, ROGIERS X, BROELSCH C: Mycophenolate mofetil for prevention of liver allograft rejection: initial results of acontrolled clinical trial. Ann. Transplant. (2000) 5:43–46.
   PubMedGoogle Scholar
• WIESNER R, RABKIN J,KLINTMALM G et al.: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Thanspl. (2001) 7:442–450.
   Google Scholar
• •The only multi-centre, randomised, double-blind study comparing mycophenolate mofetil and azathioprine in LT recipients.
   Google Scholar
• HEBERT ME ASCHER NL, LAKE JR et al.: Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation (1999) 67:707–712.
   Google Scholar
• PLATZ KP, MUELLER AR,NEUHAUS R, KECK HH, LOBECK H, NEUHAUS P: FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. Transplant. Proc. (1997), 29:2872–2874.
   PubMed Web of Science ®Google Scholar
• PFITZMANN R, KLUPP J,LANGREHR JM et al.: Mycophenolate mofetil for treatment of ongoing or chronic rejections after liver transplantation. Transplant. Proc. (2002) 34:2938–2939.
   Google Scholar
• PFITZMANN R, KLUPP J,LANGREHR JM et al.: Mycophenolate mofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation (2003) 76:130–136.
   Google Scholar
• DALY I, JAIN A, REYES J, FUNG J: Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. Transplant. Proc. (2002) 34:1503.
   PubMedGoogle Scholar
• GAVLIK A, GOLDBERG MG, TSAROUCHA A et al.: Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant. Proc. (1997) 29:549–552.
   PubMed Web of Science ®Google Scholar
• GAVLIK A, DEMIRBAS A,TSAROUCHA A et al.: Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant. Proc. (1997) 29:2971–2972.
   Google Scholar
• KATO T, RUIZ P, DEFARIA W et al.: Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Transplant. Proc. (1999) 31:396.
   PubMedGoogle Scholar
• RINGE B, BRAUN F, SCHUTZ E et al: A novel management strategy of steroid-free immunosuppression after livertransplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation (2001) 71:508–515.
   PubMedGoogle Scholar
• WASHBURN K, SPEEG KV, ESTERL R et al.: Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation (2001) 72: 1675-1679.
   Google Scholar
• FIGUERAS J, BERNARD OS A, PRIETO M et al: Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant. Proc. (2002) 34:1511–1513.
   PubMed Web of Science ®Google Scholar
• STEGALL MD, WACHS ME,EVERSON G et al: Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation (1997) 64: 1755-1760.
   Google Scholar
• PERSSON H, NORDEN G, KARLBERG I, FRIMAN S: Glomerular filtration rate after liver transplantation with a low-dose cyclosporin protocol. Transpl Int. (1994) 7:172–176.
   PubMedGoogle Scholar
• BARKMANN A, NASHAN B, SCHMIDT HH et al.: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation (2000) 69:1886–1890.
   PubMedGoogle Scholar
• PFITZMANN R, KLUPP J,LANGREHR JM et al.: Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation. Transplant. Proc. (2002) 34:2936–2937.
   Google Scholar
• HOD GE EE, REICH DJ, CLAVIEN PA, KIM-SCHLUGER L: Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. Transplant. Proc. (2002) 34:1546–1547.
   PubMedGoogle Scholar
• TORRAS J, FIGUERAS J, LAMA C et al: Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.Transplant. Proc. (1999) 31:2430.
   PubMedGoogle Scholar
• RAIMONDO ML, DAGHER L, PAPATHEODORIDIS GV et al.: Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 75:186–190.
   PubMedGoogle Scholar
• CANTAROVICH M, TZIMAS GN, BARKUN J, DES CHENES M,ALPERT E, TCHERVENKOV J: Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation (2003) 76:98–102.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, O'BEIRNE J, MISTRY P, DAVIDSON B, ROLLES K, BURROUGHS AK: Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation (1999) 68:155–157.
   PubMedGoogle Scholar
• HERRERO JI, QUIROGA J, SANGRO B et al.: Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl. Sing. (1999) 5:414–420.
   PubMedGoogle Scholar
• DETRY 0, DE ROOVER A, HONORE P, DELWAIDE J, JACQUET N, MEURISSE M: Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure. Transplant. Proc. (2002) 34:782–783.
   PubMedGoogle Scholar
• SCHLITT HJ, BARKMANN A, BOKER KH et al.: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 357:587–591.
   PubMed Web of Science ®Google Scholar
• •A randomised study advocating mycophenolate mofetil monotherapy in stable LT recipients with renal impairment due to calcineurin inhibitor toxicity.
   Google Scholar
• STEWART SF, HUDSON M, TALBOT D, MANAS D, DAY CP: Mycophenolate mofetil monotherapy in liver transplantation. Lancet (2001) 357:609–610.
   PubMedGoogle Scholar
• ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, GONZALEZ L, HERRERA-ACOSTA J, TAPIA E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. (1999) 55:945–955.
   PubMed Web of Science ®Google Scholar
• BIRKELAND SA, ANDERSEN HK, HAMILTON-DUTOIT SJ: Preventing acute rejection, Epstein-Barr virus infection,and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation (1999) 67:1209–1214.
   PubMed Web of Science ®Google Scholar
• GONG ZJ, DE MEYER S, CLARYSSE C et al.: Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. Viral Hepat. (1999) 6:229–236.
   PubMedGoogle Scholar
• NEYTS J, ANDREI G, DE CLERCQ E: The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. (1998) 42:216–222.
   PubMed Web of Science ®Google Scholar
• HOSSAIN MM, COULL JJ,DRUSANO GL, MARGOLIS DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. (2002) 55:41–52.
   PubMedGoogle Scholar
• BEN-ARI Z, ZEMEL R, TUR-KASPA R: The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance-no beneficial effect. Transplantation (2001) 71:154–156.
   PubMedGoogle Scholar
• FASOLA CG, NETTO GJ,JENNINGS LW et al.: Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant. Proc. (2002) 34:1563–1564.
   Google Scholar
• BAHRA M, NEUMANN UP,HARREN M et al.: Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. Transplant. Proc. (2002) 34:2934–2935.
   Google Scholar
• PLATZ KP, MUELLER AR,WILLIMSKI C et al.: Indication for mycophenolate mofetil therapy in hepatitisC patients undergoing liver transplantation. Transplant. Proc. (1998) 30:2232–2233.
   Google Scholar
• JAIN A, KASHYAP R, DEMETRIS AJ, EGHSTESAD B, POKHARNA R, FUNG JJ: A prospective randomized trial of mycophenolate mofetil in liver transplantrecipients with hepatitis C. Liver Transpl. (2002) 8:40–46.
   PubMedGoogle Scholar
• BUNCHMAN T, NAVARRO M, BROYER M et al: The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr. Nephrol (2001) 16:978–984.
   PubMed Web of Science ®Google Scholar
• BROWN NW, AW MM,MIELI-VERGANI G, DHAWAN A, TREDGER JM: Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effects of cyclosporine and tacrolimus comedication. Titer: Drug Monit. (2002) 24:598–606.
   PubMed Web of Science ®Google Scholar
• CHARDOT C, NICOLUZZI JE, JANSSEN M et al.: Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation (2001) 71:224–229.
   PubMedGoogle Scholar
• AW MM, SAMAROO B, BAKER AJ et al:Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. Transplantation (2001) 72:746–749.
   PubMedGoogle Scholar
• PATERSON DL, SINGH N, PANEBIANCO A et al.: Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation (1998) 66:593–598.
   PubMed Web of Science ®Google Scholar
• SEIKALY MG: Mycophenolate mofetil - is it worth the cost? The in-favor opinion. Pediatr. Transplant. (1999) 3:79–82.
   PubMedGoogle Scholar
• SULLIVAN SD, GARRISON LP, BEST JH: The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. US Renal Transplant Mycophenolate Mofetil Study Group. I Am. Soc. Nephrol (1997) 8:1592–1598.
   PubMedGoogle Scholar